🔗 Share this article

While America continues making sweeping revisions to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by questioning Covid vaccinations throughout the pandemic and has zeroed in on potential fatalities after Covid vaccination in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Agency leaders were set to unveil sweeping revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with many the international standard with no evidence for public health gain. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

Consolidating Power at the FDA

This interim role might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry roughly the size of Wisconsin’s.

To date statements, she has continued to focus on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, oversight or management, which has been typical for past leaders of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a sizeable institution. She is not an expert in industry regulation.”

Past directors of CBER would “be deeply familiar with legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who ran CBER have had.”

This division has an vast range of responsibilities at the FDA, she stated.

“The public just zeroes in on the new drug program, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one must be managed,” she said. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership element to the job, which supervises over 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” the former official concluded.

Response and Controversial Programs

In response to questions about Høeg’s qualifications and whether this selection signifies more teamwork among FDA leaders on immunizations, a spokesperson said that the “questions are based on incorrect premises”.

“Her experience is consistent with the duties of her job,” the official said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed expedited drug-approval program that reportedly concerned her predecessors. “By what process are these medications being selected for this expedited pathway? Who takes the choices?” Dr. Howard said. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, aside from vaccines.”

Public History on Vaccines

With vaccines, Høeg has a more established, if troubling, history, critics said. She authored a study using non-validated public submissions to estimate the rate of heart inflammation after Covid vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are riskier than they are.

Part of her “policy goals” for the current federal leadership featured altering guidelines for recently developed shots and discontinuing “optional” immunizations, she said following the vote on a audio program. At the FDA, Høeg has allegedly floated the idea of excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an complete ideologue who commences with her beliefs and works backwards to accommodate the evidence in a extremely disingenuous, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other skeptics, {like|